The FDA approved lenacapavir, a twice-yearly HIV prevention injection, offering a potentially transformative approach to combating the epidemic. Clinical trials showed near-complete protection, exceeding the effectiveness of daily pills. While hailed as a breakthrough, the high cost ($28,000 annually) raises concerns about accessibility, particularly in low-income countries despite Gilead's efforts to provide lower-cost versions. Reduced foreign aid further complicates widespread access.

Prepared by Olivia Bennett and reviewed by editorial team.